## SUPPLEMENTAL MATERIAL





Figure S1. **Pulmonary immune cell analysis of WT and STING N153S mice.** (A–F) Flow cytometry analysis of immune cells isolated from the lungs of WT and STING N153S mice. Total numbers were determined for the following immune cell subsets:  $CD3^+$  (A),  $CD4^+$  (B),  $CD3^+$  (C),  $CD19^+$  (D),  $CD11b^+$  (E), and  $CD49b^+$  populations (F). Data represent the mean  $\pm$  SEM of n = 3 mice per group. \*, P < 0.005, \*\*\*, P < 0.0005 by unpaired *t* test.

**JEM** 



Figure S2. **IFN**- $\beta$  and ISG expression in primary STING N154S patient skin fibroblasts, STING N153S MEFs, and transfected 293T cells. (A–F) Cells were stimulated with increasing amounts of 2'3'-cGAMP (2, 4, and 8 µg), herring testes DNA (htDNA; 0.1, 0.5, and 1 µg) and polyinosinic–polycytidylic acid (poly I:C; 0.1, 0.5, and 1 µg) for 6 h. There was no significant difference cGAMP-transfected WT and STING N153S MEFs or between healthy control and STING N154S skin fibroblasts. Data were analyzed by ANOVA. (G) ISG expression in 293T cells 24 h after overexpression of WT mouse or mutant STING N153S as previously described (Dobbs et al., 2015). \*\*\*, P < 0005; \*\*\*\*, P < 0.0001 by *t* test. Stimulations were performed in biological triplicates, and qRT-PCR was performed in technical triplicates. Data represent the mean  $\pm$  SEM.

## Table S1. Antibodies used in CyTOF

Tag	Target	Clone	Manufacturer	Catalog #
089Y	CD45	30-F11	Fluidigm	3089005B
141Pr	pSHP2	D66F10	Fluidigm	3141002A
142Nd	Caspase 3 (Cleaved)	D3E9	Fluidigm	3142004A
143Nd	TCRβ	H57-597	Fluidigm	3143010B
145Nd	CD4	RM4-5	Fluidigm	3145002B
146Nd	CD8a	53-6.7	Fluidigm	3146003B
147Sm	pSTAT5	47	Fluidigm	3147012A
148Nd	CD11B (Mac-1)	M1/70	Fluidigm	3148003B
149Sm	p4E-BP1	236B4	Fluidigm	3149005A
150Nd	CD25	3C7	Fluidigm	3150002B
151Eu	Ly-6G	1A8	Fluidigm	3151010B
153Eu	pSTAT1	58D6	Fluidigm	3153003A
154Sm	TER119	TER-119	Fluidigm	3154005B
155Gd	pTBK1/NAK	D52C2	CST	5483BF
158Gd	pSTAT3	4/P-Stat3	Fluidigm	3158005A
159Tb	ΤCRγδ	GL3	Fluidigm	3159012B
160Gd	CD45R (B220)	RA3-6B2	Fluidigm	3160012B
161Dy	pBAD	40A9	Fluidigm	3161006A
164Dy	ΙκΒα	L35A5	Fluidigm	3164004A
165Ho	CD3e	145-2C11	Fluidigm	3165020B
166Er	CD19	6D5	Fluidigm	3166015B
168Er	Ki67	B56	Fluidigm	3168007B
170Er	NK1.1	PK136	Fluidigm	3170002B
171Yb	CD44	IM7	Fluidigm	3171003B
172Yb	pS6	N7-548	Fluidigm	3172008A
173Yb	CD117 (c-kit)	2B8	Fluidigm	3173004B
174Yb	MHCII	M5/114.15.2	Fluidigm	3174003B
176Yb	pCREB	87G3	Fluidigm	3176005A

Table S2. Definition	of populations	used in CyTOF	<sup>=</sup> analysis
----------------------	----------------	---------------	-----------------------

Cell populations	Marker expression	
Fig. 5		
CD4 (CD4 T cells)	CD45 <sup>+</sup> TER119 <sup>-</sup> CD3 <sup>+</sup> CD4 <sup>+</sup> TCR $\beta^+$	
CD8 (CD8 T cells)	CD45 <sup>+</sup> TER119 <sup>-</sup> CD3 <sup>+</sup> CD8 <sup>+</sup> TCR $\beta^+$	
NK (NK cells)	CD45 <sup>+</sup> TER119 <sup>-</sup> NK1.1 <sup>+</sup> CD3 <sup>-</sup>	
CD19 (B cells)	CD45 <sup>+</sup> TER119 <sup>-</sup> CD19 <sup>+</sup> B220 <sup>+</sup> MHCII <sup>+/int/lo</sup>	
Ly6G+ (CD11b <sup>hi</sup> Ly6G <sup>hi</sup> )	CD45 <sup>+/Io</sup> TER119 <sup>-</sup> CD11b <sup>hi</sup> Ly6G <sup>hi</sup>	
Monocytes	CD45 <sup>+</sup> TER119 <sup>-</sup> CD11b <sup>+</sup> Ly66 <sup>-</sup> MHCII <sup>-</sup>	
Immature myeloid	CD45 <sup>lo</sup> TER119 <sup>-</sup> CD117 <sup>+/lo</sup> CD11b <sup>+</sup> Ly6G <sup>int/lo/-</sup>	
CD3 double-negative (DN)	CD45 <sup>+</sup> TER119 <sup>-</sup> CD3 <sup>+</sup> CD4 <sup>-</sup> CD8 <sup>-</sup>	
Fig. 6		
CD4 <sup>+</sup> CD8 <sup>-</sup>	CD45+ TER119- B220- CD19- NK1.1- CD4+ CD8-	
CD8 <sup>+</sup> CD4 <sup>-</sup>	CD45 <sup>+</sup> TER119 <sup>-</sup> B220 <sup>-</sup> CD19 <sup>-</sup> NK1.1 <sup>-</sup> CD8 <sup>+</sup> CD4 <sup>-</sup>	
CD4 <sup>+</sup> CD8 <sup>+</sup>	CD45* TER119 <sup>-</sup> B220 <sup>-</sup> CD19 <sup>-</sup> NK1.1 <sup>-</sup> CD4* CD8*	
CD4 <sup>-</sup> CD8 <sup>-</sup>	CD45+ TER119- B220- CD19- NK1.1- CD4- CD8-	
CD19 <sup>+</sup> B220 <sup>+</sup>	CD45+ TER119- B220+ CD19+	
NK1.1 <sup>+</sup>	CD45+ TER119- B220- CD19- NK1.1+	
DN1	CD45 <sup>+</sup> TER119 <sup>-</sup> B220 <sup>-</sup> CD19 <sup>-</sup> NK1.1 <sup>-</sup> CD4 <sup>+</sup> CD4 <sup>+</sup> CD4 <sup>+</sup> CD25 <sup>-</sup>	
DN2	CD45 <sup>+</sup> TER119 <sup>-</sup> B220 <sup>-</sup> CD19 <sup>-</sup> NK1.1 <sup>-</sup> CD4 <sup>+</sup> CD8 <sup>+</sup> CD44 <sup>+</sup> CD25 <sup>+</sup>	
DN3	CD45 <sup>+</sup> TER119 <sup>-</sup> B220 <sup>-</sup> CD19 <sup>-</sup> NK1.1 <sup>-</sup> CD4 <sup>+</sup> CD8 <sup>+</sup> CD25 <sup>+</sup> CD44 <sup>I0/-</sup>	
DN4	CD45 <sup>+</sup> TER119 <sup>-</sup> B220 <sup>-</sup> CD19 <sup>-</sup> NK1.1 <sup>-</sup> CD4 <sup>+</sup> CD4 <sup>+</sup> CD4 <sup>+</sup> CD25 <sup>-</sup>	
Fig. 7		
B cells	CD45 <sup>+</sup> TER119 <sup>-</sup> CD3 <sup>-</sup> CD19 <sup>+</sup>	
T cells	CD45* TER119" CD19" CD3*	
Monocytes	CD45 <sup>+</sup> TER119 <sup>-</sup> CD3 <sup>-</sup> CD19 <sup>-</sup> CD11b <sup>+</sup> Ly6G <sup>-</sup> MHCII <sup>-</sup>	
NK cells	CD45+ TER119- CD19- CD3- NK1.1+	
Immature myeloid	CD45 <sup>+</sup> TER119 <sup>-</sup> CD3 <sup>-</sup> CD19 <sup>-</sup> CD11b <sup>+</sup> MHCII <sup>-</sup>	

## REFERENCE

Dobbs, N., N. Burnaevskiy, D. Chen, V.K. Gonugunta, N.M. Alto, and N.Yan. 2015. STING activation by translocation from the ER is associated with infection and autoinflammatory disease. *Cell Host Microbe.* 18:157–168. http://dx.doi.org/10.1016/j.chom.2015.07.001